Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: Role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring

Journal of Viral Hepatitis

Volumn 5, Issue 1, 1998, Pages 61-66

  Lobello, S ^a   Lorenzoni, U ^a   Vian, A ^a   Floreani, A ^a   Brunetto, M R ^b   Chiaramonte, M ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Div Gastroenterologia   (Italy)

Author keywords

Chronic hepatitis; Chronic liver disease; HBcAb IgM; HBeAb positive; HBV; Interferon treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIBODY; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LYMPHOBLAST INTERFERON; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS INFECTION;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; DNA, VIRAL; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULIN M; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES;

EID: 0031850278     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00083.x     Document Type: Article

References (22)

1. Bonino F, Rosina F. Rizzetto M et al. Chronic hepatitis in HBsAg carriers with serum HBV DNA and anti-HBe. Gastroenterology 1986; 90: 1268-1273.
2. Brunetto M R, Stemler M, Bonino F et al. A new hepatitis virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990; 10: 258-261.
3. Santantonio T, Jung MC, Miska S, Pastore G, Pape GR, Will H. High prevalence of heterogenicity of HBV pre C-mutants in anti-HBe positive carriers with chronic liver disease in Southern Italy. J Hepatol 1991; 13 (suppl 4): S78-S81.
4. Brunetto MR, Giarin M, Olivieri F et al. e-Antigen defective hepatitis B virus and course of chronic infection. J Hepatol 1991; 13 (suppl 4): S82-S86.
5. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
6. Brunetto MR, Olivieri F, De Martini A et al. Treatment with IFN of chronic hepatitis associated with antibody to hepatitis e-Antigen. J Hepatol 1991; 1 (suppl): S8-S11.
7. Thomas HC, Karayiannis P, Brook G. Treatment of the hepatitis B virus infection with IFN. Factors predicting response to IFN. J Hepatol 1991; 13: S4-S7.
8. Tinè F, Liberati A, Craxì A, Almasio P, Pagliaro L. IFN treatment in patients with chronic hepatitis B: a metaanalysis of published literature. J Hepatol 1993; 18: 154-162.
9. Pastore G, Santantonio T, Milella M et al. Anti-HBe positive chronic hepatitis B with HBV DNA in the serum response to a 6 month course of lymphoblastoid interferon. J Hepatol 1992; 14: 221-225.
10. Fattovich G, Farci P, Brollo R et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 584-589.
11. Rumi MG, Romeo R, De Filippi F et al. A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B. Ital J Gastroenterol 1993; 25: 117-120.
12. Alberti A, Fattovich G. Interferon therapy for the anti-HBe positive form of chronic hepatitis B. Antiviral Res 1994; 24: 145-153.
13. Jianye X, Brown D, Harrison T. Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to IFN-alpha. Hepatology 1992; 15: 1002-1006.
14. Brunetto MR, Giarin M, Saracco G et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845-850.
15. Talbodec N, Loriot MA, Gigou M et al. Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy. Liver 1995; 15: 93-98.
16. Milich DR. Immune response to the hepatitis B virus proteins: relevance of the murine model. Semin Liver Dis 1991; 11: 93-112.
17. Carreno V, Bartolomè J, Castillo I. Long-term effect of IFN therapy in chronic hepatitis B. J Hepatol 1994; 20: 431-435.
18. Brunetto MR, Torrani Cerenza M, Olivieri F, Piantino P, Randone A, Calvo P. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semiquantitative assay for IgM-antiHBc. J Hepatol 1993; 19: 431-436.
19. Marinos G, Smith H, Naumov NV, Williams R. Quantitative assessment of serum IgM antiHBc in the natural course and during IFN treatment of chronic hepatitis B virus infection. Hepatology 1994; 19: 303-311.
20. Hadziyannis SJ, Hadziyannis AS, Dourakis S, Alexopoulou A, Horsch A, Hess G. Clinical significance of quantitative antiHBc IgM assay in acute and chronic HBV infection. Hepato Gastroenterol 1993; 40: 588-592.
21. Smith HM, Johnson YN, Davies SE, Daniels HM, Alexander GJ, Williams R. Significance of serum IgM antiHBc in chronic hepatitis B infection. J Med Virol 1992; 36: 16-20.
22. De Franchis R, Meucci G, Vecchi M et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-194.